🔍

JAGSNPHARM - Jagsonpal Pharma

📊 NSE: JAGSNPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:32

📢 Recent Corporate Announcements

Jagsonpal Pharma Receives ₹4.82 Crore Income Tax Demand for AY 2024-25

🔵 WATCH ⭐ 4/10

LEGAL 📅 13 Mar 2026, 08:25 PM

Jagsonpal Pharmaceuticals has received a tax demand notice of ₹4.82 crore from the Income Tax Department for the Assessment Year 2024-25. The demand stems from the disallowance of certain expenses claimed by the company in its tax returns. The company plans to contest this order by filing an appeal with the relevant Appellate Authority. Management has indicated that they believe the case has merit and do not expect any material financial impact on the company's operations.

Tax demand of ₹4,81,61,360 issued under Section 156 of the Income Tax Act, 1961.
The order pertains to Assessment Year 2024-25 following a faceless assessment under Section 143(3).
Demand is based on the disallowance of specific expenses claimed in the company's income tax return.
Company is preparing to file an appeal before the Appellate Authority within prescribed timelines.
Management expects no material financial impact as they believe the company has a strong legal position.

💡 Investors should monitor the progress of the tax appeal, though the current demand of ₹4.82 crore is relatively small compared to the company's scale and unlikely to impact long-term fundamentals.

Jagsonpal Pharma Approves ₹40 Cr Buyback at ₹250 Per Share via Tender Offer

🟢 POSITIVE ⭐ 7/10

OTHER 📅 12 Mar 2026, 02:03 PM

Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh equity shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total outlay of ₹40 crore, which constitutes 18.35% of the company's net worth as of March 2025. The process will be conducted via the tender offer route, allowing existing shareholders to participate on a proportionate basis. Notably, the promoter group has decided not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-buyback.

Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total buyback size of ₹40 crore represents 18.35% of paid-up capital and free reserves
The offer is conducted through the tender offer route on a proportionate basis
Promoters will not participate, leading to an indicative stake increase from 67.2% to 68.9%
Centrum Capital Limited has been appointed as the Manager to the Buyback

💡 Investors should compare the ₹250 offer price with the current market price to evaluate potential arbitrage or exit opportunities. The non-participation of promoters is a positive signal and may lead to a higher acceptance ratio for retail shareholders.

Jagsonpal Pharma Board Approves ₹40 Crore Buyback at ₹250 Per Share via Tender Route

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 12 Mar 2026, 02:02 PM

Jagsonpal Pharmaceuticals has announced a buyback of 16 lakh shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total cash outlay of ₹40 crore, which is 18.35% of the company's net worth. The process will be conducted through the tender offer route, allowing shareholders to participate on a proportionate basis. Notably, the promoters have opted not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-completion.

Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total offer size of ₹40 crore represents 18.35% of paid-up capital and free reserves
Buyback to be executed via the tender offer route on a proportionate basis
Promoters and Promoter Group will not participate in the buyback offer
Centrum Capital Limited appointed as the Manager to the Buyback

💡 Investors should evaluate the buyback price of ₹250 against the current market price for potential arbitrage or exit opportunities. Since promoters are not participating, the acceptance ratio for retail shareholders is likely to be higher.

Jagsonpal Pharmaceuticals Grants 11.52 Lakh ESOPs at Rs 139 Exercise Price

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Mar 2026, 03:50 PM

Jagsonpal Pharmaceuticals has approved the grant of 11,52,500 employee stock options under its 2022 ESOP Plan. The options are exercisable at a price of Rs 139.00 per share, which will eventually convert into an equivalent number of equity shares of face value Rs 2.00 each. The vesting of these options is scheduled over four years in equal annual tranches of 25% each, starting from the first anniversary of the grant. This move is aimed at long-term employee retention and aligning staff interests with shareholder value.

Approved the grant of 11,52,500 employee stock options under the 2022 Plan.
Exercise price set at Rs 139.00 per option, significantly above the Rs 2.00 face value.
Vesting period structured in 4 equal annual tranches starting March 2027.
Total grant represents approximately 4.4% of the current total equity share capital.

💡 Investors should treat this as a routine corporate action for talent retention; however, be mindful of the gradual equity dilution that will occur as these options vest and are exercised over the next four years.

Jagsonpal Pharmaceuticals Grants 11.52 Lakh ESOPs at Exercise Price of Rs 139

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Mar 2026, 03:45 PM

Jagsonpal Pharmaceuticals has approved the grant of 11,52,500 employee stock options under its 2022 ESOP plan. These options are exercisable at a price of Rs. 139.00 per share, which will eventually be converted into equity shares of face value Rs. 2.00. The vesting will occur in four equal annual installments starting one year from the grant date. This move is designed to align employee interests with shareholder value and improve long-term talent retention.

Grant of 11,52,500 employee stock options approved under the 2022 ESOP Plan.
Exercise price fixed at Rs. 139.00 per option for conversion into equity shares.
Vesting schedule spread over 4 equal annual tranches starting from the first anniversary.
Options are convertible into equity shares with a face value of Rs. 2.00 each.

💡 Investors should note the potential for minor equity dilution over the next four years as options are exercised. No immediate action is required as this is a standard talent retention strategy.

Jagsonpal Pharma Q3 PAT Rises 10% to ₹12.5 Cr; Management Guides for Q4 Recovery

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 03:16 PM

Jagsonpal Pharmaceuticals reported a flattish Q3 FY26 with revenue at ₹73 crores, though PAT grew 10% YoY to ₹12.5 crores. The company faced headwinds as its relevant market (RPM) grew only 3-3.5% compared to the broader pharma market's 8% growth. Management attributed the performance to internal recalibrations and leadership transitions, including a ₹2.1 crore one-time provision for the new labor code. Despite the slow quarter, the company maintains a strong cash position of ₹176 crores and expects double-digit growth to resume from Q4 FY26.

Q3 FY26 Revenue stood at ₹73 crores, while 9M FY26 revenue grew 6% YoY to ₹223 crores.
PAT for the quarter increased by 10% YoY to ₹12.5 crores with margins improving 180 bps to 17.1%.
Free cash balance reached ₹176 crores, reflecting an increase of ₹15.2 crores during the quarter.
Exceptional item of ₹2.1 crores provided for past service costs related to the new labor code.
Management expects growth acceleration to double digits starting from Q4 FY26 following field force recalibration.

💡 Investors should monitor the promised recovery in Q4 to see if internal leadership changes and strategy refreshes translate into higher volume growth. The strong cash position and debt-free status provide a significant cushion for future expansion or acquisitions.

Jagsonpal Pharmaceuticals Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 22 Jan 2026, 07:04 PM

Jagsonpal Pharmaceuticals has officially released the audio recording of its Q3 FY26 earnings conference call held on January 22, 2026. The recording covers management's discussion regarding the company's financial performance and operational updates for the quarter. This disclosure is part of the company's regulatory compliance under SEBI (LODR) Regulations, 2015. Shareholders and analysts can access the recording via the company's investor relations portal to understand the nuances of the quarterly results.

Audio recording of the Q3 FY26 earnings call is now available for public access.
The conference call was conducted on January 22, 2026, at 5:00 P.M. IST.
The filing is in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).
Recording provides insights into management's commentary on the third-quarter financial results.

💡 Investors should listen to the recording to understand management's outlook on the pharmaceutical sector and specific growth drivers for Jagsonpal.

Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Reserves

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 21 Jan 2026, 07:10 PM

Jagsonpal Pharmaceuticals reported a steady performance for 9MFY26 with Operating PAT growing 12.5% YoY to ₹359 million. While Q3 revenue was largely flat at ₹729 million, the company achieved significant margin expansion, with Operating PAT margins rising 160 bps to 17.1%. A key highlight is the robust cash balance of ₹1,757 million, which increased by ₹152 million during the quarter. Management has expressed confidence in stronger growth starting from Q4 FY26, backed by new product launches and focused initiatives.

9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%.
Q3FY26 Operating PAT increased 10% YoY to ₹125 Mn despite a marginal 1% dip in revenue to ₹729 Mn.
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant liquidity for inorganic growth.
Operating EBITDA (pre-ESOP) for 9MFY26 stood at ₹503 Mn, reflecting a 5% YoY increase.
The company provided ₹21 Mn in Q3 for potential past service costs related to the new labour code.

💡 Investors should monitor the company's ability to translate its high cash reserves into inorganic growth through brand or business acquisitions. The stock remains attractive due to its asset-light model and margin expansion, but the promised growth acceleration in Q4 will be a key performance indicator.

Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Position

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 21 Jan 2026, 07:09 PM

Jagsonpal Pharmaceuticals reported a 12.5% YoY increase in Operating PAT for 9MFY26, reaching ₹359 million, despite a modest 6% revenue growth. For the Q3FY26 quarter, revenue was slightly down by 1% at ₹729 million, but Operating PAT grew by 10% to ₹125 million as margins expanded to 17.1%. The company maintains a very strong liquidity position with a cash balance of ₹1,757 million, increasing by ₹152 million during the quarter. Management remains optimistic about stronger growth starting from Q4 FY26.

9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%
Q3FY26 Revenue remained flat at ₹729 Mn, while Operating PAT rose 10% to ₹125 Mn
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant inorganic growth potential
Operating EBITDA margins remained resilient at 22.7% for Q3 and 22.6% for the nine-month period
Company provided ₹21 Mn for additional past service costs related to the new labor code

💡 Investors should focus on the company's ability to maintain high margins and its massive cash pile for potential M&A. Monitor Q4 results to see if the promised growth acceleration materializes.

Jagsonpal Pharma Q3 Operating PAT up 10% to ₹125 Mn; Cash Reserves Reach ₹1,757 Mn

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 21 Jan 2026, 07:07 PM

Jagsonpal Pharmaceuticals reported a 12.5% YoY growth in 9MFY26 Operating PAT to ₹359 million, driven by operational discipline and a 6% revenue increase. For Q3FY26, while revenue was flat at ₹729 million, Operating PAT rose 10% YoY to ₹125 million with margins expanding to 17.1%. The company's cash balance strengthened significantly to ₹1,757 million, providing a solid foundation for future inorganic growth. Management has signaled a more aggressive growth trajectory starting from Q4 FY26.

9MFY26 Operating PAT rose 12.5% YoY to ₹359 Mn; Operating PAT margins expanded by 95 bps to 16.1%
Q3FY26 Revenue remained stable at ₹729 Mn, while Operating PAT increased 10% YoY to ₹125 Mn
Cash and equivalents increased by ₹152 Mn during the quarter to reach a total of ₹1,757 Mn
Operating EBITDA (pre-ESOP) for 9MFY26 grew 5% YoY to ₹503 Mn with a 22.6% margin
A provision of ₹21 Mn was made in Q3 for past service costs related to the new labor code

💡 Investors should monitor the promised growth acceleration in Q4 FY26 and potential inorganic acquisitions using the company's significant cash reserves. The stock remains a steady play on domestic chronic and sub-chronic pharma segments with improving profitability.

Jagsonpal Pharma Q3 Net Profit Falls 17.8% YoY to ₹10.98 Cr; Revenue Flat at ₹72.9 Cr

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 21 Jan 2026, 05:10 PM

Jagsonpal Pharmaceuticals reported a marginal YoY revenue decline to ₹729.45 million for the quarter ended December 31, 2025. Net profit dropped significantly by 17.8% YoY to ₹109.78 million, primarily weighed down by a ₹20.79 million exceptional charge related to new labor code transitions. While 9-month revenue showed a 6.1% growth to ₹2,230.22 million, overall profitability for the period is lower than the previous year. The company is also dealing with a ₹15.20 million GST demand, which it intends to appeal.

Q3 Revenue from operations stood at ₹729.45 million vs ₹740.25 million in the previous year's quarter.
Net Profit for Q3 declined to ₹109.78 million from ₹133.57 million YoY.
Exceptional expense of ₹20.79 million recognized due to the enactment of New Labour Codes affecting employee benefits.
9-month revenue grew 6.1% YoY to ₹2,230.22 million, though 9-month profit fell to ₹320.53 million from ₹345.74 million.
Company is contesting a ₹15.20 million GST demand from the Haryana SGST office regarding ITC mismatches.

💡 The decline in both quarterly revenue and profit suggests a challenging operating environment; investors should wait for signs of margin recovery. Monitor the integration of the Yash Pharma business and the resolution of the GST demand for future impact.

Jagsonpal Pharmaceuticals to Host Q3 FY26 Earnings Conference Call on January 22, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 15 Jan 2026, 04:47 PM

Jagsonpal Pharmaceuticals Limited has scheduled its Q3 FY26 earnings conference call for Thursday, January 22, 2026, at 5:00 PM IST. The call will focus on the financial performance for the third quarter and the nine-month period ending December 31, 2025. Investors can participate via universal dial-in numbers +91 22 6280 1557 or +91 22 7115 8383. This routine disclosure is part of the company's investor engagement activities hosted by Go India Advisors.

Earnings conference call scheduled for January 22, 2026, at 5:00 PM IST
Discussion to cover Q3 FY26 and 9MFY26 financial results
Universal dial-in numbers provided: +91 22 6280 1557 and +91 22 7115 8383
Pre-registration available via Diamond Pass to bypass wait times
Event hosted by Go India Advisors for institutional and retail investors

💡 Investors should monitor the upcoming Q3 results and attend the call to understand management's guidance on product pipeline and margin sustainability. Pay close attention to any updates regarding the company's expansion strategy in the domestic pharmaceutical market.

Jagsonpal Pharmaceuticals Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 05:15 PM

Jagsonpal Pharmaceuticals Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, provided by MCS Share Transfer Agent Limited, confirms that securities received for dematerialization were processed within the mandatory 15-day period. It ensures that physical certificates were cancelled and the depository's name was updated in the company's records. This is a standard regulatory filing required for all listed entities to ensure the integrity of shareholding data.

Compliance certificate submitted for the quarter ended December 31, 2025.
Dematerialization requests were processed within the 15-day regulatory window.
Physical share certificates were mutilated and cancelled after due verification by the Registrar.
The filing confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required from investors as this is a routine administrative filing. Investors should focus on the company's upcoming financial results for material performance updates.

Jagsonpal Pharmaceuticals Allots 1.09 Lakh Equity Shares Under ESOP 2022

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Jan 2026, 05:03 PM

Jagsonpal Pharmaceuticals has allotted 1,09,180 equity shares to eligible employees upon the exercise of vested options under its 2022 ESOP plan. The allotment increases the company's total paid-up share capital from Rs. 13.36 crore to Rs. 13.38 crore. The shares were issued at exercise prices of Rs. 94.00 and Rs. 115.60 per share. This represents a marginal equity dilution of approximately 0.16%, which is considered a routine corporate action for employee retention.

Allotment of 1,09,180 equity shares with a face value of Rs. 2 each.
Exercise prices fixed at Rs. 94.00 for 1,05,200 shares and Rs. 115.60 for 3,980 shares.
Total paid-up equity shares increased from 6,67,81,270 to 6,68,90,450.
The new shares will rank pari-passu with existing equity shares in all respects.
The resulting equity dilution is minimal at approximately 0.16%.

💡 No action is required as this is a routine administrative allotment with negligible impact on the company's valuation. Investors should focus on the company's upcoming quarterly earnings and growth guidance.

Jagsonpal Pharma Receives GST Demand of INR 1.52 Crores for FY 2021-22

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 30 Dec 2025, 04:52 PM

Jagsonpal Pharmaceuticals has received a tax demand order from the SGST authority in Gurugram for the financial year 2021-22. The total demand amounts to INR 1.52 Crores, which includes a tax component of INR 84.89 Lakhs, interest of INR 58.60 Lakhs, and a penalty of INR 8.49 Lakhs. The demand arises from alleged mismatches in Input Tax Credit (ITC) and E-waybill reporting. The company intends to appeal the order and does not anticipate any material financial impact on its operations.

Total tax demand of INR 1,51,98,726 received from Haryana SGST authorities.
Breakdown includes INR 84.89 Lakhs tax, INR 58.60 Lakhs interest, and INR 8.49 Lakhs penalty.
Issues relate to ITC mismatches between GSTR-2A/3B and E-waybill discrepancies for FY 2021-22.
Company plans to file an appeal and believes it has a strong case on merits.
Management states no material impact is expected on operations or financials.

💡 Investors should treat this as a routine regulatory matter with minimal impact on long-term value. Monitor for any further escalations in tax liabilities, but no immediate action is required.

View All JAGSNPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue for H1 FY26 reached INR 150.1 Cr, a 10.2% YoY increase. Q2 FY26 revenue was INR 74.5 Cr, a marginal 0.3% YoY decline due to GST 2.0 transition adjustments. Key segments include Gynaecology, Orthopaedics, Dermatology, and Child-care, with Dydrogesterone growing from zero to INR 40 Cr within 18 months of launch.

Geographic Revenue Split

The company maintains an extensive pan-India distribution network; however, specific percentage splits by region are not disclosed in the available documents.

Profitability Margins

Net Profit Ratio improved significantly to 20.6% in FY 2024-25 from 10.8% in FY 2023-24. Q2 FY26 PAT margin expanded by 154 bps YoY to 16.9%, driven by improved business performance and operational efficiencies post-acquisition of Yash Pharma.

EBITDA Margin

Operating EBITDA margin (pre-ESOP) for Q2 FY26 stood at 24.3%, a slight 39 bps decline from 24.6% YoY. H1 FY26 Operating EBITDA grew 8.8% YoY to INR 33.8 Cr, reflecting efficient cost management and the successful integration of Yash Pharma's profitability to JPL levels.

Capital Expenditure

The company follows an asset-light model with minimal capital expenditure plans as it has transitioned to complete outsourcing of manufacturing operations to contract manufacturers.

Credit Rating & Borrowing

Long-term rating reaffirmed at [ICRA]BBB(Positive) and short-term rating upgraded to [ICRA]A2. The company maintains a robust financial risk profile with nil debt and a strong cash balance of INR 160.4 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed; however, the company procures and supplies raw materials to a pool of contract manufacturers to maintain strict control over product quality.

Key Suppliers

The company utilizes a pool of third-party contract manufacturers rather than owning manufacturing plants, though specific vendor names are not listed.

Capacity Expansion

Current strategy focuses on 'complete outsourcing of manufacturing operations,' eliminating the need for owned capacity expansion. Growth is driven by brand acquisitions and new product launches rather than physical plant expansion.

Raw Material Costs

Raw material costs are managed by supplying inputs to contract manufacturers to mitigate quality risks. Trade payables increased in FY 2024-25 specifically due to the Yash Pharma business acquisition.

Manufacturing Efficiency

Efficiency is driven by an asset-light model. Inventory Turnover Ratio increased to 17.6 in FY 2024-25 from 13.9 in FY 2023-24, reflecting better inventory planning and control.

Logistics & Distribution

The company operates an extensive pan-India distribution network. Current Ratio decreased to 6.2 in FY 2024-25 from 9.5 in FY 2023-24 as surplus funds were utilized for the Yash Pharma acquisition.

📈 Strategic Growth

Expected Growth Rate

10.20%

Growth Strategy

Growth is targeted through a three-pronged strategy: 1) New product launches (e.g., Dydrogesterone), 2) Strategic acquisitions like Yash Pharma to expand the portfolio, and 3) Improving Medical Representative (MR) productivity to drive higher accretive value from existing fixed costs.

Products & Services

Pharmaceutical formulations in the form of medicines for Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Brand Portfolio

Divatrone, Maintane, J.P. Tone, Indocap, and Dydrogesterone.

New Products/Services

New product launches are a core driver; Dydrogesterone contributed ~15% of revenue (approx INR 40 Cr) within 18 months of its FY2022 launch.

Market Expansion

Expansion is focused on the Indian Pharmaceutical Market (IPM), which grew at 7.5% in Q2 FY26. JPL aims to outpace market growth through its 'double-engine' leadership and expanded portfolio.

Market Share & Ranking

Not disclosed as a specific percentage, but identified as a leading player with a 50+ year legacy in specialized segments like Gynaecology.

Strategic Alliances

The company acquired brands from Yash Pharma Private Limited (YPPL) in Q1 FY2025 for an estimated INR 93 Cr to strengthen its market position.

🌍 External Factors

Industry Trends

The Indian pharma market is growing at ~7.5%, driven by price increases. Trends show a shift toward high-margin products and increased regulatory scrutiny on manufacturing standards.

Competitive Landscape

Intense competition from contract manufacturers, MNCs, and established domestic brands, particularly affecting legacy brands like Divatrone and Maintane.

Competitive Moat

Moat is built on a 50-year brand legacy, a robust portfolio in niche segments (Gynaecology), and a strong pan-India distribution network. Sustainability is supported by an asset-light, high-liquidity financial model.

Macro Economic Sensitivity

Sensitive to Indian Pharmaceutical Market (IPM) trends and government healthcare policies like GST 2.0, which aims for affordable healthcare.

Consumer Behavior

Shift toward 'Patient First' approaches and affordable healthcare, influenced by government price reductions passed through GST 2.0.

Geopolitical Risks

The industry faces general regulatory trends and macro-economic condition changes, though JPL's focus is primarily domestic.

⚖️ Regulatory & Governance

Industry Regulations

Approximately 6-7% of revenues are subject to price control. The company must also comply with Ind AS and the Companies Act, 2013.

Taxation Policy Impact

The company transitioned to GST 2.0 in Q2 FY26, passing on price reduction benefits to patients, which caused a temporary moderation in sales.

Legal Contingencies

No material lapses or fraud were reported by internal auditors. The company has a 'Jagsonpal Pharmaceuticals Limited ESOP Plan 2022' in compliance with SEBI SBEBS Regulations.